Canadian CRO partners with Italian CRO for imaging services

By Zachary Brennan

- Last updated on GMT

Canadian CRO partners with Italian CRO for imaging services
Canadian CRO ADA Medical will collaborate with Italy’s Ephoran Multi-Imaging Solutions to expand into the pre-clinical research space. 

ADA Medical currently provides research and quality assured based pre-clinical contract services focused on inflammatory, oncology and cardiovascular diseases and will build on Ephoran’s technology.

The collaboration is a two-way partnership. Ephoran provides cutting edge equipment and facilities, imaging services and in-vivo modeling​,” ADA spokesman Daniel Beaulieu told us. “ADA Medical provides clinical research, scientific and program management oversight​.”

This new molecular imaging CRO service based near Turin, Italy will conduct pre-clinical drug development modeling and assessments.

ADA Medical’s existing project management, pharmacodynamics, pharmacokinetics, biostatistics, data management and regulatory/quality assurance capabilities will bring needed GLP, pre-clinical management and quality oversight to create the discipline needed for drug research and support of drug research submissions.

ADA Medical is the exclusive agent for Ephoran​,” Beaulieu told us. “All pre-clinical imaging work will be conducted in Italy at Ephoran's facility near Turin. ADA Medical's North American network will provide pre-clinical and scientific reporting​.”

Ephoran is a reference centre for a number of imaging technologies and this expansion into drug development aims to fill a void in the pre-clinical drug imaging sector.

Imaging technology provides significant biological data that will be used to verify the efficacy of a drug compound and make the drug development process much more effective and quicker​,” said Vito Lorusso, VP of Ephoran.

Related topics: Preclinical Research, Phase III-IV

Related news

Show more

Related products


Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers